Papers by Thomas Corbridge
Chest, Oct 1, 2020
Background: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-i... more Background: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. Methods: IMPACT was a 52-week, randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of FF/UMEC/VI 100/62.5/25 mcg with FF/VI 100/25 mcg or UMEC/VI 62.5/25 mcg in patients ≥40 years of age with symptomatic chronic obstructive pulmonary disease (COPD) and ≥1 moderate/severe exacerbation in the previous year. The inclusion criteria for the study were intentionally designed to permit the enrollment of patients with significant concurrent CV disease/risk. CV safety assessments included proportion of patients with and exposure-adjusted rates of on-treatment CV adverse events of special interest (CVAESI) and major adverse cardiac events (MACE), as well as time-to-first (TTF) CVAESI, and TTF CVAESI resulting in hospitalization/prolonged hospitalization or death. Results: Baseline CV risk factors were similar across treatment groups. Overall, 68% of patients (n = 7012) had ≥1 CV risk factor and 40% (n = 4127) had ≥2. At baseline, 29% of patients reported a current/past cardiac disorder and 58% reported a current/past vascular disorder. The proportion of patients with on-treatment CVAESI was
C40. PREDICTING OUTCOMES AND NEW THERAPIES IN CHRONIC OBSTRUCTIVE LUNG DISEASE, 2020
Respiratory Research, 2020
Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic antagonist/l... more Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy administered via single or multiple inhalers in patients with chronic obstructive pulmonary disease (COPD) has not been evaluated comprehensively. We conducted two replicate trials comparing single- with multiple-inhaler ICS/LAMA/LABA combination in COPD. Methods 207608 and 207609 were Phase IV, 12-week, randomized, double-blind, triple-dummy non-inferiority trials comparing once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg via Ellipta inhaler, with twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg via metered-dose inhaler plus once-daily tiotropium (TIO) 18 μg via HandiHaler. Patients had symptomatic COPD and forced expiratory volume in 1 s (FEV1) < 50% predicted, or FEV1 < 80% predicted and ≥ 2 moderate or 1 severe exacerbations in the prior year. The primary endpoint in both trials was weig...
Textbook of Critical Care, 2011
The Journal of Allergy and Clinical Immunology: In Practice
The Journal of allergy and clinical immunology, 2009
Noninvasive positive pressure ventilation (NPPV) offers ventilatory assistance for respiratory fa... more Noninvasive positive pressure ventilation (NPPV) offers ventilatory assistance for respiratory failure. There are 2 principal forms used: continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP). Both provide positive airway pressure during the respiratory cycle, but BiPAP offers pressure in a biphasic manner, with higher pressures during inspiration than expiration. Studies in patients with obstructive lung disease indicate that low-level CPAP offsets the detrimental effects of auto–positive end-expiratory pressure, which are caused by gas trapped in alveoli at end expiration and decrease inspiratory work of breathing. The addition of inspiratory pressure support to CPAP (or BiPAP) generally improves tidal volume in proportion to the amount of pressure applied. Both CPAP and BiPAP have been used as an alternative to intubation in patients with a variety of respiratory conditions, including congestive heart failure with pulmonary edema and chronic obst...
The Journal of allergy and clinical immunology, 2009
Disclosure of potential conflict of interest: M. Schatz has been a consultant for GlaxoSmithKline... more Disclosure of potential conflict of interest: M. Schatz has been a consultant for GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline and Merck. A. A. N. Kazzi has declared that he had no conflict of interest. B. Brenner has declared that he had no conflict of interest. C. A. Camargo Jr has been a consultant, speaker, or advisory board member for AstraZeneca, Critical Therapeutics, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from the National Institutes of Health, AstraZeneca, Critical Therapeutics, GlaxoSmithKline, Merck, Novartis, and Respironics. T. Corbridge is on the speakers' bureau for GlaxoSmithKline. J. A. Krishnan has declared that he had no conflict of interest. R. Nowak has declared that he had no conflict of interest. G. Rachelefsky has been a speaker or advisory board member for AstraZeneca, Schering-Plough, CSL Behring, Merck, and Sanofi Aventis and has provided legal consultation or expert witness testimony on the topic of environmental injuries, mostly mold-related. This article is part of the Joint Task Force Report: Supplemental Recommendations for the Management and Follow-up of Asthma Exacerbations, an official statement of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Emergency Medicine (AAEM), and the American Thoracic Society (ATS).
The Journal of emergency medicine, 2009
Disclosure of potential conflict of interest: M. Schatz has been a consultant for GlaxoSmithKline... more Disclosure of potential conflict of interest: M. Schatz has been a consultant for GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline and Merck. A. A. N. Kazzi has declared that he had no conflict of interest. B. Brenner has declared that he had no conflict of interest. C. A. Camargo Jr has been a consultant, speaker, or advisory board member for AstraZeneca, Critical Therapeutics, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from the National Institutes of Health, AstraZeneca, Critical Therapeutics, GlaxoSmithKline, Merck, Novartis, and Respironics. T. Corbridge is on the speakers' bureau for GlaxoSmithKline. J. A. Krishnan has declared that he had no conflict of interest. R. Nowak has declared that he had no conflict of interest. G. Rachelefsky has been a speaker or advisory board member for AstraZeneca, Schering-Plough, CSL Behring, Merck, and Sanofi Aventis and has provided legal consultation or expert witness testimony on the topic of environmental injuries, mostly mold-related.
B103. TREATMENT OF OBSTRUCTIVE LUNG DISEASE, 2020
Proceedings of the American Thoracic Society, 2009
Academic medicine : journal of the Association of American Medical Colleges, Jan 26, 2017
In 2012, the Northwestern University Feinberg School of Medicine launched a redesigned curriculum... more In 2012, the Northwestern University Feinberg School of Medicine launched a redesigned curriculum addressing the four primary recommendations in the 2010 Carnegie Foundation for the Advancement of Teaching report on reforming medical education. This new curriculum provides a more standardized evaluation of students' competency achievement through a robust portfolio review process coupled with standard evaluations of medical knowledge and clinical skills. It individualizes learning processes through curriculum flexibility, enabling students to take electives earlier and complete clerkships in their preferred order. The new curriculum is integrated both horizontally and vertically, combining disciplines within organ-based modules and deliberately linking elements (science in medicine, clinical medicine, health and society, professional development) and threads (medical decision making, quality and safety, teamwork and leadership, lifestyle medicine, advocacy and equity) across the...
American journal of respiratory and critical care medicine, Oct 22, 2016
Chest Journal, Feb 1, 2003
Intensivists are confronted with poisoned patients on a routine basis, with clinical scenarios ra... more Intensivists are confronted with poisoned patients on a routine basis, with clinical scenarios ranging from known drug overdose or toxic exposure, illicit drug use, suicide attempt, or accidental exposure. In addition, drug toxicity can also manifest in hospitalized patients from inappropriate dosing and drug interactions. In this review article, we describe the epidemiology of poisoning in the United States, review physical examination findings and laboratory data that may aid the intensivist in recognizing a toxidrome (symptom complex of specific poisoning) or specific poisoning, and describe a rational and systematic approach to the poisoned patient. It is important to recognize that there is a paucity of evidence-based information on the management of poisoned patient. However, the most current recommendations by the American Academy of Clinical Toxicology and European Association of Poisons Centers and Clinical Toxicologists will be reviewed. Specific poisonings will be reviewed in the second section of these review articles.
The American Journal of Nursing, May 1, 2010
More than 16 million U.S. adults have asthma, a condition that prompts 2 million ED visits and ne... more More than 16 million U.S. adults have asthma, a condition that prompts 2 million ED visits and nearly half a million hospital admissions annually. Management of this potentially deadly, chronic inflammatory disease depends on early diagnosis, accurate classification, appropriate treatment, and targeted patient education. This article outlines current guideline recommendations for asthma and reviews what clinicians need to teach patients about its pathophysiology, pharmacotherapy, self monitoring, and environmental control. The authors discuss the classic clinical presentation of the disease, describe how to assess severity and control, and explain how such assessments can guide management.
Uploads
Papers by Thomas Corbridge